Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination products containing limonoids and thiazolidinediones

A technology of limonoids and thiazolidinedione, applied in the field of medicine, can solve problems such as moderate edema, mild anemia, and hypoglycemia in patients

Active Publication Date: 2021-06-29
NATURAL MEDICINE INST OF ZHEJIANG YANGSHENGTANG
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The main side effects of thiazolidinedione drugs are: it is not suitable for patients with type I diabetes or diabetic ketoacidosis; when used alone in high doses or in combination with insulin and other oral hypoglycemic drugs, patients may experience hypoglycemia and abnormal liver function , moderate edema, risk of mild anemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination products containing limonoids and thiazolidinediones
  • Combination products containing limonoids and thiazolidinediones
  • Combination products containing limonoids and thiazolidinediones

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Effects of limonoids, rosiglitazone or their combination on blood glucose in mouse islet β-cell injury model

[0035] In this example, ICR mice were modeled with streptozotocin (STZ) to obtain a mouse islet β-cell injury model (Li Nan et al., The protective effect of pine pollen on kidney damage in mice with diabetic nephropathy, Science and Technology Herald, 2014, 32 (4 / 5): 95-99), completed the animal hypoglycemic efficacy evaluation experiment (this model can simulate type I and type II diabetes islet β cell damage state). Limonoid compounds choose limonin, isocitrin acid, limonin glycoside, and isocitrolactone glycoside, and set up separate rosiglitazone administration group, limonin administration group, and isocitrolactone administration group. acid administration group, limonin glycoside administration group, isocitrolactone glycoside administration group and combined administration group compounded with rosiglitazone.

[0036] Experimental feeding conditions: ...

Embodiment 2

[0047] Effects of limonoids, pioglitazone, or their combination on blood glucose and leptin in a mouse model of type II diabetes

[0048] In this embodiment, db / db mice (strain name BKS.Cg-Dock7 m+ / + Lepr db / Nju) completed the animal hypoglycemic efficacy evaluation experiment (blood sugar level and leptin). Limonoid compounds were selected from phellodendrones, isofortone glucosides and phellodendron glucosides, and a separate pioglitazone administration group, phellodendron ketone administration group, isofertuodenic acid administration group, phellodendron glucoside administration group and Combined administration group of pioglitazone.

[0049] Experimental feeding conditions: as type II diabetes model mice, 6-week-old SPF-grade db / db mice were purchased from the Nanjing Institute of Model Organisms, and the experimental feeding was carried out after 7 days of preparatory feeding. It should be noted that the feeding conditions of the mice were temperature of 23±1°C, hu...

Embodiment 3

[0061] Effects of limonoids, pioglitazone or their combination on blood glucose in mouse islet β-cell injury model

[0062] In this example, ICR mice were modeled with streptozotocin (STZ) to obtain a mouse islet β-cell injury model (Li Nan et al., The protective effect of pine pollen on kidney damage in mice with diabetic nephropathy, Science and Technology Herald, 2014, 32 (4 / 5): 95-99), completed the animal hypoglycemic efficacy evaluation experiment (this model can simulate type I and type II diabetes islet β cell damage state). For limonoid compounds, choose Yichang Hesin, Yichang Hesin, and Yichang Hesin Glycoside, and set up a separate pioglitazone administration group, Yichang Hesin administration group, Yichang Gensin administration group, and Yichang Hesin Glycoside administration group. Drug group and combined administration group compounded with pioglitazone.

[0063] Experimental feeding conditions: ICR mice (20±2g), 6 weeks old, were purchased from Zhejiang Acad...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a compound containing limonoids (and pharmaceutically acceptable derivatives, esters, stereoisomers, salts or prodrugs thereof) and thiazolidinedione drugs (such as rosiglitazone, pioglitazone, etc. ) combination products. The present invention also relates to the use of the combined product in treating and / or preventing diseases related to diabetes.

Description

technical field [0001] The invention belongs to the technical field of medicine, in particular to a limonoid compound (and pharmaceutically acceptable derivatives, esters, stereoisomers, salts or prodrugs thereof) and thiazolidinedione drugs (or their pharmaceutically acceptable derivatives, esters, stereoisomers, salts or prodrugs) Combination products of pharmaceutically acceptable derivatives). The present invention also relates to the use of the combined product in treating and / or preventing diabetes and diseases related to metabolic syndrome. Background technique [0002] According to IDF statistics, there were about 425 million people with diabetes worldwide in 2017, and 1 in every 11 people has diabetes. The number of diabetic patients in China is about 110 million, ranking first in the world. It is predicted that by 2040, there will be 642 million people with diabetes worldwide, and 151 million people with diabetes in China. Diabetes requires lifelong monitoring a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/06A61K31/4439A61K31/585A61P3/10A61P3/00
CPCA61K45/06A61K31/4439A61K31/585A61P3/10A61P3/00A61K2300/00A61K31/366A61K31/7048A61K9/2054A61K9/2095
Inventor 李栋韩铨胡柳薛莲
Owner NATURAL MEDICINE INST OF ZHEJIANG YANGSHENGTANG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com